1. Home
  2. List
Reference Patent

Reference - List

  • 50 Hits
  • Search Condition : Filter (MeSH = Protein Kinase Inhibitors / therapeutic use)
Species Resource Title
DNA material tFucci(CA)2/pCSII-EF (RDB15446) A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.
Human and Animal Cells RBE(RCB1292) EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.
Human and Animal Cells Ba/F3 Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.
Human and Animal Cells Ba/F3-CL1(RCB4474) Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.
Human and Animal Cells Li-7(RCB1941) WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.
Human and Animal Cells PK-45H(RCB1973) , PK-59(RCB1901) , MIA Paca2(RCB2094) , PANC-1(RCB2095) , PK-1(RCB972) Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor.
Human and Animal Cells 9-15C(RCB2323) A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia.
Human and Animal Cells ME-180(RCB2160) , Ca Ski(RCB1947) Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
Human and Animal Cells Ba/F3(RCB4476) , LC-2/ad(RCB0440) Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
DNA material mVenus-hGeminin(1/110) / pCSII-EF (RDB15271) , mCherry-hCdt1(30/120)/ pCSII-EF (RDB15273) Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects.
Human and Animal Cells Rat-1(RCB1830) Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells.
Human and Animal Cells Ba/F3 NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Human and Animal Cells StromaNKtert(RCB2350) Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
Human and Animal Cells Ba/F3(RCB0805) Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Human and Animal Cells PC-9(RCB4455) MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements.
Human and Animal Cells 293(RCB1637) , G-361(RCB0991) , A549(RCB3677) , T24(RCB2536) , A431(RCB0202) , PANC-1(RCB2095) , HCT116(RCB2979) , 293gp(RCB2354) Qualitative differences in disease-associated MEK mutants reveal molecular signatures and aberrant signaling-crosstalk in cancer.
Human and Animal Cells Ba/F3(RCB0805) , WEHI-3(RCB0035) Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Human and Animal Cells 8505C(RCB2103) , HTC/C3(RCB0452) , HOTHC(RCB0662) BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.
Human and Animal Cells 293T(RCB2202) Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.
Human and Animal Cells HTC/C3(RCB0452) Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.